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PERSPECTIVES IN CLINICAL NEPHROLOGY
Is /32-microglobulin a mediator of bone disease?
Elevated serum and tissue concentrations of 2-microglobulin
are universally found among patients with chronic renal insuffi-
ciency. A new type of amyloidosis affecting patients undergoing
long-term dialytic therapy is related to the accumulation of
2-microglobulin [1—19]. This amyloidosis, also termed AB-amy-
loidosis, /32-microglobulin amyloidosis, or dialysis related amy-
loidosis, is manifested clinically by the carpal tunnel syndrome,
erosive and destructive osteoarthropathies, and cystic bone lesions
[6, 10, 14, 19, 20]. Although most commonly seen in patients
following long-term hemodialysis therapy, f32-microglobulin amy-
loidosis also occurs in patients treated exclusively by continuous
ambulatory peritoneal dialysis [1, 2] or prior to the initiation of
dialytic therapy [19]. The incidence of these complications in-
creases with the age of the patient and the duration of renal
failure and/or replacement therapy [21—23]. Biochemical and
immunohistologic studies have demonstrated that f32-microglobu-
un is the major protein constituent of the amyloid fibrils in these
patients [3, 8, 17]. However, the pathologic role of 2-microglobu-
un in amyloid formation and development of osseous lesions is
poorly understood. Many issues concerning j32-microglobulin
amyloidosis remain unresolved. The following discussion will
focus on two fundamental questions regarding the etiology of the
2-microglobulin associated lesion: (1) is the formation of amy-
bid fibrils a primary event resulting from increased circulating
concentrations of 32-microglobulin; and (2) does 132-microglobu-
un or the f32-microglobulin-amyloid fibril play an active role in
inducing bone destruction or is it an innocent bystander?
Metabolism
132-microglobulin is a nonglycosylated polypeptide composed of
100 amino acids arranged in a single polypeptide chain with a
molecular weight of 11,800 Daltons. The synthesis of f32-micro-
globulin has been estimated to range between 50 and 200 mg/day
[24]. It is present on the surface of all nucleated cells as an integral
part of the HLA class I antigen complex but may also be found in
non-HLA-associated forms [25—27] with lymphoid cells, predom-
inantly T cells, having the greatest surface density [28]. Hepato-
cytes appear to possess the greatest synthetic capacity, thus the
liver is most probably the main organ responsible for circulating
32-microglobulin concentrations under both normal and patho-
logic conditions [29]. Intracellular levels of f32-microglobulin are
regulated by endogenous mediators, predominantly a- and y-in-
terferon [29—31]. After shedding from cell surfaces or intracellu-
lar release, more than 90% of the 132-microglobulin circulates in
the monomeric form that is not protein bound [18, 32].
f32-microglobulin is almost exclusively catabolized within the
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kidney. At least 95% and possibly 100% of the circulating
132-microglobulin is eliminated via glomerular filtration [24], re-
absorbed in the proximal tubule and subsequently degradated by
proteolytic enzymes [33—35]. Thus, approximately 150 to 200 mg
of J32-microglobulin are metabolized daily by normal kidneys.
Although extrarenal sites of f32-microglobulin catabolism may
exist, none have been clearly demonstrated. In normal individuals
the serum concentration of /32-microglobulin is usually less than 2
mg/liter and the urinary excretion less than 400 g/24 hr [34, 36,
37].
Increased synthesis and release of 32-microglobulin, as indi-
cated by an elevation of serum 132-microglobulin concentrations,
occurs in inflammatory and malignant diseases including rheu-
matic disorders, infectious diseases, acquired immunodeficiency
and lymphoproliferative disorders [38—41]. Both T and B cell
antigens increase cellular /32-microglobulin release [42, 43]. In
vitro and in vivo studies demonstrated that the synthesis and
release of /32-microglobulin are mediated by various cytokines.
Tumor necrosis factor (TNF), interleukin-2 (IL-2), and both a-
and y-interferon (INF) stimulate the synthesis and release of
j32-microglobulin from various cell types in culture [11, 29, 44, 45].
In vivo application of TNF or a- and y-INF increases serum
/32-microglobulin concentrations [29, 45]. Whereas IL-i has not
been shown to have an stimulatory effect on 2-microglobulin
synthesis or release in vitro [11, 29, 44, 45}, a stimulatory effect of
IL-i via the in vivo induction of other cytokines is probable [46].
The most important cause of increased f32-microglobulin concen-
trations is the reduced clearance associated with renal failure,
where serum concentrations are increased to more than 50-fold
the normal range [4, 21].
Several years ago it was observed that the type of hemodialysis
therapy may affect serum 2-microglobulin concentrations. An
increase in /32-microglobulin concentration during dialysis with
cuprophane membranes and a decrease during dialysis with
synthetic membranes were observed [9, 47]. The increased levels
may result from dialysis membrane bioincompatibility, triggering
complement activation and C5a and C3a formation, leading to
sequestration and activation of leukocytes, which then promote
132-microglobulin synthesis and release [32, 48]. Alternatively it
has been suggested that increased f32-microglobulin synthesis
occurs as a result of a marked and rapid lowering of plasma
osmolality or oncotic pressure during hemodialysis [11, 49]. The
role of the hemodialysis treatment and type of membrane remain
controversial. Campistol et al evaluated in vitro 2-microglobulin
synthesis in lymphocyte cultures and were unable to demonstrate
an effect of hemodialysis modality or membrane type on 132-
microglobulin synthesis [50], whereas Zaoui, Stone and Hakim
clearly demonstrated that lymphocytes cultured from patients
dialyzed with cuprophane membranes produced significantly
more f32-microgbobulin than patients dialyzed with synthetic mem-
branes [51]. Similar to the findings of Campistol and colleagues
[50], Zingraff et al also demonstrated no effect of the cuprophane
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membrane to stimulate in vitro f32-microglobulin synthesis in
whole blood from both normal individuals and hemodialysis
patients [47]. Furthermore, the addition of IL-i and IL-6 to
lymphocyte cultures did not increase f32-microglobulin synthesis,
whereas the addition of normal rabbit serum did [50]. More work
is required to elucidate which factors are important in inducing
f32-microglobulin synthesis during dialysis.
132-Microglobulin as an amyloidogenic protein
Serum /32-microglobulin levels in patients with chronic renal
failure with and without clinical or histological amyloidosis are
similar. Thus, additional factors other than the increased circu-
lating concentrations of f32-microglobulin must be involved in the
development of amyloidosis [4, 5, 12, 13, 16, 21, 52, 53]. The
f32-microglobulin molecule contains two anti-parallel /3-pleated
sheets, and its three-dimensional structure resembles the domains
of IgG [25]. The /3-structure of the molecule suggests an intrinsic
capacity for the formation of amyloid fibrils. In fact, the sponta-
neous generation of f32-microglobulin amyloid fibrils has been
achieved in vitro with high concentrations of /32-microglobulin in
salt-free solutions [54]. Spontaneous in vitro aggregation of 132-
microglobulin into amyloid fibrils has also been demonstrated
with bovine /32-microglobulin [55] and from protein originating
from mononuclear cells of dialysis patients [56]. These findings
suggest that, unlike other types of amyloidosis where a proteolytic
process is required, /32-microglobulin may not require a proteo-
lytic phase or cell processing.
Several observations, however, strongly argue against simple
precipitation of 132-microglobulin as the mechanism of amyloido-
genesis. It has been observed that not only intact f32-microglobu-
lin, but also a 24 kDa dimer and various fragments of 132-
microglobulin are involved in amyloid formation [52]. Linke and
colleagues [52] demonstrated that proteases can cleave the lysine
residue located at the amino-terminal of /32-microglobulin, thus
increasing its hydrophobic tendency and inducing amyloid forma-
tion. They have subsequently demonstrated the presence of
protease modified /32-microglobulin fragments in situ in amyloid
deposits isolated from chronic dialysis patients [53]. Gejyo,
Homma and Arakawa have identified a 7.4 kDa fragment consist-
ing of /32-microglobulin residues from amyloid renal calculi in
chronic dialysis patients, which was not due to a lysine-specific
cleavage [6]. In addition to intact f32-microglobulin, a "novel
/32-microglobulin" with a reduced molecular weight has been
identified from solubilized amyloid fibrils as well as in the plasma
of hemodialysis patients with clinical f32-microglobulin amyloid-
osis [16]. This protein exhibited a more acidic isoelectric point
than normal f32-microglobulin. Subsequently, other investigators
have identified several acidic isoforms of f32-microglobulin in
serum and urine from both uremic and nonuremic individuals [57,
58]. Other than a circulating dimeric form of /32-microglobulin
isolated only from uremic serum [57], it appears that these
circulating acidic isoforms are not necessarily specific for amyloid-
ogenisis [57, 58]. Miyata et al [12] have also isolated an acidic
32-microglobulin from amyloid fibrils, serum and urine of affected
hemodialysis patients which was not present in normal individuals.
This acidic isoform comprised the majority of /32-microglobulin
found in the amyloid fibrils. The electrogenic heterogeneity of
132-microglobulin was not due to deamination as previously pro-
posed [8, 16], but a result of Maillard reaction causing advanced
glycation end product modification of circulating J32-microglobu-
lin [12].
In addition to the post translational modification of /32-micro-
globulin, substances other than J32-microglobulin may facilitate
the amyloidogenesis of J32-microglobulin. We have observed
increased incidence of /32-microglobulin amyloidosis with de-
creased circulating concentrations of amyloid P component, sug-
gesting increased tissue uptake of amyloid P component in the
pathogenesis of the amyloidosis [21]. The glycosaminoglycans
(GAG) composition of the interstitial matrix of the tissue may
also be a local factor favoring amyloid formation, as suggested by
ultrastructural and immunohistochemical studies of /32-micro-
globulin amyloid deposits in hemodialysis patients [15]. Electron
probe analysis has demonstrated the presence of calcium within
the amyloid deposition, suggesting the importance of calcium in
the amyloidogenic process [7]. Other proteins, in addition to
132-microglobulin and its fragments, have also been identified from
amyloid deposits. Argiles and colleagues identified c2-macroglob-
ulin in amyloid deposits and suggested that the progression of the
amyloid was due to suppressed decomposition of amyloid fibrils
by a2-macroglobulin [59]. Brancaccio and colleagues have identi-
fled a new 85 kDa protein contained in synovial amyloid deposits
of hemodialysis patients at a molar ratio equivalent to /32-
microglobulin, however whether this protein is involved with
amyloidogenesis has yet to be determined [60].
The predilection for j32-microglobulin amyloid deposits to
osteo-articular tissues, which are rich in collagen, suggests an
affinity of /32-microglobulin for collagen. In fact it has been
demonstrated that /32-microglobulin preferentially binds to vari-
ous types of collagen in a dose dependent manner [61]. The
affinity of /32-microglobulin for collagen is greater than for pro-
teoglycan or heparan sulfate. Spiegel and co-workers have also
observed that both amyloid P component and /32-microglobulin
are found associated with collagen in the dermis of dialysis
patients, and their relative concentrations are related to the
duration of dialysis [62].
132-Microglobulin as a bone growth factor
Bone cells produce f32-microglobulin and the so-called bone-
derived growth factor (BDGF). BDGF, a bone growth factor
originally isolated from rat calvariae and subsequently isolated
from bovine bone matrix, is now known to be /32-microglobulin
[63, 64]. The amino acid composition of BDGF is compatible with
murine /32-microglobulin and the amino-terminal sequence is
identical with murine f32-microglobulin. f32-microglobulin appears
to have a mitogenic effect on murine bone cells as human
f32-microglobulin and isolated BDGF similarly stimulate DNA
production, collagen and non-collagen protein synthesis in iso-
lated osteoblast cultures [63, 65, 66]. However, utilizing isolated
chicken osteoblasts, Jennings, Mohan and Baylink were unable to
demonstrate a mitogenic effect of human /32-microglobulin, and
the mitogenic effect of bovine bone matrix-derived /32-micro-
globulin was attributable to contamination with transforming
growth factor-/3 [64]. In murine calvarial cultures, neither we [67]
nor others [63] were able to demonstrate a mitogenic effect of
human /32-microglobulin. The incongruity observed in [3H]-thy-
midine incorporation between isolated osteoblast and calvarial
cultures suggests that additional components of bone may also be
affected by f32-microglobulin, complicating the interpretation of
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this experimental measurement. Further supporting such com-
plexity, Evans, Thavarajan and Kanis demonstrated that, although
osteoblasts respond to and produce f32-microglobulin, /32-micro-
globulin does not affect the production of alkaline phosphatase or
osteocalcin by isolated osteoblasts [66]. Similarly, we were unable
to demonstrate an effect of /32-microglobulin on alkaline phos-
phatase release [67]. Whether the mitogenic effect of f32-micro-
globulin on osteoblasts is a direct effect or a result of contamina-
tion or augmentation of other growth factors requires further
evaluation.
Molecules of the major histocompatibility complex interact with
hormonal receptors, and some investigators believe that 132-
microglobulin might not be a typical growth factor but a regulator
of the growth-promoting effects of other growth factors. Centrella,
McCarthy and Canalis have demonstrated that the mitogenic
effect of insulin-like growth factor I (IGF-I) on bone cells is
augmented by f32-microglobulin. In osteoblast enriched cell cul-
tures, /32-microglobulin enhances IGF-I receptor number, in-
creases IGF-I transcripts and polypeptide levels [65]. The stimu-
latory effects of f32-microglobulin appears to be selective since it
does not enhance transforming growth factor 13 (TGF-13) recep-
tors or transcripts [65]. Although still controversial, the evidence
accumulated thus far suggests that /32-microglobulin has a physi-
ologic function in bone remodeling.
32-Microglobulin as a bone resorbing agent
Experimental data demonstrating that, in addition to the dep-
osition of 32-microglobulin-amyloid at sites of osteo-articular
damage, f32-microglobulin is directly involved in causing osteoar-
ticular disease has been provided by several investigators. Subcu-
taneous injections of 132-microglobulin induces histologic evidence
of bone resorption in neonatal mice [68]. It is unclear if this
observation following local injection is analogous to the effects of
circulating 32-microglobulin. However, we have demonstrated
that purified human 132-microglobulin induces a dose- and time-
dependent net calcium efflux from cultured neonatal mouse
calvariae [67, 69]. The observation that the f32-microglobulin-
induced calcium efflux could be inhibited by calcitonin, required
an incubation period of at least 48 hours and is associated with the
release of the osteoclast enzymes, f3-glucuronidase and acid
phosphatase, is consistent with a cell-mediated phenomenon and
suggests stimulated osteoclastic bone resorption. The significant
time delay supports the hypothesis that 132-microglobulin acts via
the activation of other factors in the complex regulation of bone
remodeling [65, 70].
Bone remodeling is controlled by hormonal and local factors in
a complex regulatory system and f32-microglobulin probably inter-
acts via several of these pathways. Using both submaximal and
pharmacologic concentrations of parathyroid hormone, we were
unable to demonstrate augmentation of calcium effiux from
calvariae incubated with parathyroid hormone and f32-micro-
globulin [67, 69]. Moreover, other studies were unable to demon-
strate an effect of parathyroid hormone on f32-microglobulin
transcription [71] or an effect of 1,25(OH)2D3 on f32-microglobu-
lin immunoreactivity [66] in osteoblast cultures. These prelimi-
nary data suggest that calciotropic hormones may not influence
132-microglobulin synthesis or action in a direct manner.
Several cytokines are known to induce bone resorption [70, 72].
Both IL-i and TNF-f3 have multiple effects on bone including
stimulation of cell mediated resorption [73—75]. Enhanced pro-
duction with elevated basal concentrations of these cytokines has
been demonstrated in patients undergoing chronic hemodialysis
[76, 77]. It is possible that these cytokines could initiate bone
resorption, thus predisposing osteo-articular structures to the
deposition of f32-microglobulin. Contrarily, the bone resorbing
effect of 132-microglobulin may be mediated by these cytokines. It
has recently been demonstrated that advanced glycation end
product-modified f32-microglobulin purified from chronic dialysis
patients stimulates production of TNF-a and IL-1/3 by macro-
phages [13]. This is consistent with our recent observation that
/32-microglobulin induced calcium release from neonatal calvariae
can be completely prevented with IL-1f3 antibody, whereas pros-
taglandin inhibition with indomethacin has no effect on the
132-microglobulin-induced calcium release from cultured bone
[78].
132-microglobulin has also been demonstrated to induce the
synthesis of fibroblast collagenase, suggesting its role in modulat-
ing connective tissue breakdown in both normal and disease states
[79]. Miyata et al demonstrated that advanced glycation end
product-modified 132-microglobulin stimulates a sufficient amount
of TNF-a and IL-1f3 to cause production of collagenase in
cultured human synovial cells [13]. Clearly more work is required
to further elucidate the relationship between the accumulation of
132-microglobulin and the evolution of progressive tissue destruc-
tion.
Conclusion
In summary, osteo-articular tissue, which is rich in collagen,
most likely has a high affinity for 132-microglobulin accumulation.
The deposition of 132-microglobulin as amyloid fibrils is not only
the result of elevated tissue concentrations and interaction with
other compounds such as P component, collagen and glycosami-
noglycans, but most likely is the result of metabolic processing
including proteolysis and/or advanced glycation end-product mod-
ification. Within osteo-articular tissues which have high endoge-
nous enzymatic activity and metabolically-altered bone remodel-
ing from underlying renal disease, 132-microglobulin most likely
further interferes with the remodeling process. Based upon the
available data we propose the following model of f32-microglobu-
lin osteo-articular destruction (Fig. 1). The increased circulating
serum concentrations of 132-microglobulin become modified into
advanced glycation end products with time. These proteins then
induce the production of IL-i and TNF-a which stimulate bone
resorption and inhibit bone formation. The TNF-a, and possibly
IL-i, also increase the local production of f32-microglobulin. In
addition, synovial cells are stimulated to produce collagenase
which further facilitates bone resorption and soft tissue destruc-
tion. The local tissue destruction induces the migration of inflam-
matory cells and the subsequent production of cytokines leading
to increased tissue destruction. The resorbed bone and surround-
ing tissues, which are rich in collagen, becomes the site of
deposition and formation of 132-microglobulin amyloid. Further
studies are required to substantiate this hypotheses and answer
the question as to why this form of amyloidosis has such a
predisposition to osteo-articular structures.
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Fig. 1. Proposed mechanism of /32-microg/obulin
tissue destruction in the pathogenesis of (32-
microglobulin amyloidosis. Abbreviations are:
AGE, advanced glycation end product; OB,
osteoblast; OC, osteoclast; SC, synovial cell.
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